BACKGROUND: The current study was conducted to analyze the association between cigarette smoking and metastasis (the primary outcome) as well as time to biochemical disease recurrence (BCR), metastasis, castration-resistant prostate cancer (CRPC), and prostate cancer-specific and overall mortality (secondary outcomes) after radical prostatectomy among men from the Shared Equal Access Regional Cancer Hospital cohort.
METHODS: A retrospective analysis was performed of 1450 subjects for whom smoking status was available from preoperative notes. Analysis of baseline characteristics by smoking status was performed using the chi-square and rank sum tests. The association between smoking status and time to the event was analyzed using Kaplan-Meier plots, the log-rank test, and Cox and competing risk models.
RESULTS: A total of 549 men (33%) men were active smokers and 1121 (67%) were nonsmokers at the time of surgery. Current smokers were younger and had a lower body mass index, higher prostate-specific antigen level, and more extracapsular extension and seminal vesicle invasion (all P < .05). A total of 509 patients, 26 patients, 30 patients, 18 patients, and 217 patients, respectively, experienced BCR, metastasis, CRPC, prostate cancer-related death, and any-cause death over a median follow-up of 62 months, 75 months, 61 months, 78 months, and 78 months, respectively. After adjusting for preoperative features, active smoking was found to be associated with an increased risk of BCR (hazards ratio [HR], 1.25; P = .024), metastasis (HR, 2.64; P = .026), CRPC (HR, 2.62; P = .021), and overall mortality (HR, 2.14; P < .001). Similar results were noted after further adjustment for postoperative features, with the exception of BCR (HR, 1.10; P = .335), metastasis (HR, 2.51; P = .044), CRPC (HR, 2.67; P = .015), and death (HR, 2.03; P < .001).
CONCLUSIONS: Among patients undergoing radical prostatectomy, cigarette smoking was associated with an increased risk of metastasis. In addition, smoking was associated with a higher risk of BCR, CRPC, and overall mortality. If confirmed, these data suggest that smoking is a modifiable risk factor in patients with aggressive prostate cancer.
Written by:
Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ. Are you the author?
The Arthur Smith Institute for Urology, North Shore Long Island Jewish Health System, New Hyde Park, New York.
Reference: Cancer. 2013 Oct 11. Epub ahead of print.
doi: 10.1002/cncr.28423
PubMed Abstract
PMID: 24127391
UroToday.com Prostate Cancer Section
